aspirin has been researched along with mci 9038 in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 5 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chattopadhyay, P; Deka, RC; Gogoi, D; Mukherjee, AK; Pal, A; Paul, S | 1 |
| Bai, T; Feng, Q; Guo, T; Jia, J; Li, X; Liu, Y; Pei, J; Song, Y; Wu, L; Wu, S; Zhang, Y; Zheng, X | 1 |
| Collen, D; Gold, HK; Imura, Y; Lesaffre, E; Stassen, JM; Vreys, I | 1 |
| Clarke, RJ; Fitzgerald, DJ; FitzGerald, GA; Mayo, G | 1 |
| Collen, D; Fallon, JT; Gold, HK; Guerrero, JL; Holt, R; Jang, IK; Leinbach, RC; Yaoita, H; Yasuda, T | 1 |
| Fukushi, H; Imura, Y; Kawamura, M; Kita, S; Moriya, N; Nishikawa, K; Sugihara, H; Terashita, Z | 1 |
| Börjesson, I; Elg, M; Gustafsson, D; Lenfors, S; Teger-Nilsson, AC | 1 |
| Koide, M; Matsuo, T | 1 |
| Hirasawa, Y; Ito, K; Kato, Y; Kita, Y; Motoyama, Y; Nishio, M; Seki, J; Yamanaka, T | 1 |
| Kobayashi, H; Koide, M; Matsuo, M; Matsuo, T; Sakamoto, S; Shimamo, C; Suzuki, S | 1 |
| Hosomi, N; Kohno, M; Mizushige, K; Ohyama, H; Takahashi, T | 1 |
| Iwata, M; Uchiyama, S; Yamazaki, M | 1 |
| Shinohara, Y | 1 |
| Oomura, M; Shigeno, K; Terai, T; Yamawaki, T | 1 |
| Shima, K | 1 |
| Allegretto, N; Barbera, F; Bird, JE; Giancarli, MR; Ogletree, ML; Schumacher, WA; Seiffert, D; Wong, P | 1 |
| Eno, S; Hondo, T; Iwamoto, A; Kimura, M; Matsuda, K; Matsumura, H | 1 |
| Kobayashi, Y; Mano, T; Matsuo, K; Nishi, R | 1 |
| Cao, S; Chen, L; Yang, J | 1 |
| Curtis, BR; Erdil, RM; Gilyard, SN; Knelson, EH; Leaf, RK; Malhotra, R; Puram, RV; Ranganathan, R; Van Beuningen, AM; Wallwork, R; Weber, BN | 1 |
| Du, Y; He, L; Liu, Q; Wang, H; Wang, J; Xu, J; Xu, X | 1 |
| Anderson, M; Chuck, C; Feler, J; Jayaraman, MV; McTaggart, R; Moldovan, K; Poggi, J; Sweeney, J; Torabi, R | 1 |
| Wu, T; Xu, S; Xu, Z; Zhang, W; Zhang, Y | 1 |
6 review(s) available for aspirin and mci 9038
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.
Topics: Fibrinolytic Agents; Humans; Molecular Structure; Thrombosis | 2022 |
[Heparin-induced thrombocytopenia].
Topics: Anticoagulants; Antithrombins; Arginine; Aspirin; Diagnosis, Differential; Fibrinolytic Agents; Heparin; Humans; Pipecolic Acids; Platelet Activation; Platelet Aggregation Inhibitors; Sulfonamides; Thrombocytopenia; Thrombosis | 1998 |
[Strategy for circulatory disturbance].
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Arginine; Aspirin; Clinical Trials as Topic; Heparin; Humans; Immunoglobulin Fab Fragments; Meta-Analysis as Topic; Pipecolic Acids; Platelet Aggregation Inhibitors; Streptokinase; Stroke; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2001 |
[Clinical guidelines for stroke].
Topics: Anticoagulants; Antipyrine; Arginine; Aspirin; Brain Edema; Edaravone; Fibrinolytic Agents; Free Radical Scavengers; Glycerol; Humans; Hyperlipidemias; Hypertension; Japan; Methacrylates; Pipecolic Acids; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Stroke; Sulfonamides; Thrombolytic Therapy; Time Factors; Warfarin | 2004 |
[Advanced medical therapy in patients with acute ischemic stroke].
Topics: Administration, Oral; Anticoagulants; Antipyrine; Arginine; Aspirin; Drug Design; Edaravone; Fibrinolytic Agents; Genomics; Heparin; Humans; Infusions, Intravenous; Pipecolic Acids; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Stroke; Sulfonamides; Time Factors; Tissue Plasminogen Activator | 2006 |
3 trial(s) available for aspirin and mci 9038
| Article | Year |
|---|---|
Combined administration of aspirin and a specific thrombin inhibitor in man.
Topics: Adult; Antithrombins; Arginine; Aspirin; Bleeding Time; Blood Coagulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Male; Pipecolic Acids; Sulfonamides | 1991 |
Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
Topics: Aged; alpha-2-Antiplasmin; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin III; Arginine; Aspirin; Biomarkers; Combined Modality Therapy; Endothelium, Vascular; Female; Fibrinolysin; Fibrinolytic Agents; Hemostasis; Heparin; Heparin Cofactor II; Humans; Inflammation; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Pipecolic Acids; Plasminogen Activator Inhibitor 1; Plasminogen Activator Inhibitor 2; Platelet Count; Prothrombin; Sulfonamides; Tissue Plasminogen Activator; von Willebrand Factor | 2000 |
[Argatroban, Aspirin, and Clopidogrel Combination Therapy for Acute Penetrating Artery Infarction: A Pilot Study].
Topics: Acute Disease; Aged; Arginine; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Infarction; Male; Middle Aged; Pilot Projects; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Stroke; Sulfonamides; Ticlopidine; Treatment Outcome | 2016 |
16 other study(ies) available for aspirin and mci 9038
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First Report of Plant-Derived β-Sitosterol with Antithrombotic, in Vivo Anticoagulant, and Thrombus-Preventing Activities in a Mouse Model.
Topics: Animals; Anticoagulants; Antithrombins; Catalysis; Disease Models, Animal; Female; Fibrinogen; Humans; Male; Mice; Plants; Platelet Aggregation Inhibitors; Sitosterols; Thrombin; Thrombosis | 2018 |
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Topics: Animals; Antithrombins; Arginine; Aspirin; Blood Coagulation; Cricetinae; Disease Models, Animal; Drug Synergism; Femoral Vein; Fibrinolytic Agents; Hemostasis; Heparin; Injections, Intravenous; Male; Peptides, Cyclic; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Count; Sulfonamides; Sulfoxides; Thrombosis | 1992 |
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Aspirin; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Dogs; Pipecolic Acids; Platelet Membrane Glycoproteins; Recurrence; Sulfonamides; Thrombolytic Therapy; Tissue Plasminogen Activator; Vascular Patency | 1990 |
Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
Topics: Alprostadil; Animals; Arginine; Aspirin; Clopidogrel; Dogs; Fibrinolytic Agents; Guanidines; Guinea Pigs; Humans; Macaca fascicularis; Male; Pipecolic Acids; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines; Sulfonamides; Ticlopidine | 1996 |
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Topics: Animals; Antithrombins; Arginine; Aspirin; Bleeding Time; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin; Male; Molecular Weight; Pipecolic Acids; Piperidines; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombolytic Therapy; Thrombophlebitis; Thrombosis | 1996 |
In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.
Topics: Arginine; Aspirin; Benzamides; Dipeptides; Dose-Response Relationship, Drug; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Thrombin; Serine Endopeptidases; Sulfonamides; Thiazoles; Thiazolidines; Thrombin | 1999 |
Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia.
Topics: Animals; Antithrombins; Arginine; Aspirin; Blood Pressure; Brain Edema; Cerebrovascular Circulation; Fibrinolytic Agents; Gerbillinae; Hippocampus; Ischemic Attack, Transient; Male; Methacrylates; Microcirculation; Nerve Degeneration; Neurons; Pipecolic Acids; Sulfonamides; Survival Rate; Thrombin | 2001 |
[A case of anterior cerebral artery dissection causing enlargement of infarction].
Topics: Anterior Cerebral Artery; Aortic Dissection; Arginine; Aspirin; Diffusion Magnetic Resonance Imaging; Female; Fibrinolytic Agents; Humans; Infarction, Anterior Cerebral Artery; Magnetic Resonance Angiography; Middle Aged; Pipecolic Acids; Sulfonamides | 2005 |
Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Chlorides; Ferric Compounds; Guinea Pigs; Hemostasis; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2008 |
A case of acute coronary artery occlusion associated with very rapid onset heparin-induced thrombosis without thrombocytopenia.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Arginine; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occlusion; Drug Therapy, Combination; Female; Heart Failure; Heparin; Humans; Pipecolic Acids; Platelet Count; Platelet Factor 4; Stents; Sulfonamides; Tetrazoles; Thrombosis; Ticlopidine; Time Factors | 2012 |
Argatroban plus aspirin versus aspirin in acute ischemic stroke.
Topics: Arginine; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Retrospective Studies; Severity of Illness Index; Statistics as Topic; Stroke; Sulfonamides; Treatment Outcome | 2018 |
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thrombosis; Drug Substitution; Drug Therapy, Combination; Eptifibatide; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Platelet Transfusion; Purpura, Thrombocytopenic, Idiopathic; Shock, Cardiogenic; ST Elevation Myocardial Infarction; Stents; Sulfonamides; Thrombectomy; Thrombolytic Therapy; Thrombosis; Ticagrelor; Warfarin | 2020 |
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet Aggregation Inhibitors; Stroke; Sulfonamides; Ticlopidine | 2022 |
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS-CoV-2; Stroke; Thrombectomy; Ticagrelor; Treatment Outcome | 2023 |
Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Prognosis; Stroke; Treatment Outcome | 2023 |